Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2022
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MSTomas Kalincik, Ilya Kister, Tamar E Bacon, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Multiple Sclerosis and Related Disorders|January 10, 2019
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort studyAi-Lan Nguyen, Eva Kubala Havrdova, Dana Horakova, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Turkish Journal of Medical Sciences|March 22, 2023
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)Meryem Aslı Tuncer, Murat Kürtüncü, Murat Terzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Pageof 15